Vertical Aerospace Announces 1,000-mile Hybrid-Electric VTOL Programme to Serve Defence, Logistics and Wider Commercial Markets
LONDON & NEW YORK--(BUSINESS WIRE)--Vertical Aerospace ('Vertical') (NYSE: EVTL) today announced it is developing a hybrid-electric vertical-take-off-and landing (VTOL) variant of its VX4 aircraft, expanding range and payload capabilities to unlock new market opportunities within the already sizable $1TR 1 total addressable urban air mobility market.
Vertical's hybrid-electric strategy builds on its all-electric VX4 and Flightpath 2030 strategy, enabling new potential applications in defence, logistics and commercial sectors including air ambulance services, which require longer range and higher payload than current eVTOL platforms can deliver.
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre, will be retrofitted into one of the company's VX4 full scale prototypes and is expected to commence flight testing in Q2 2026.
Key targeted capabilities of Vertical's hybrid-electric variant:
Range: Up to 1,000 miles, a 10-fold increase from its all-electric aircraft.
Payload: Configurable to carry up to 1,100 kilograms in the VX4's class-leading airframe capacity.
Stealth advantages: Low noise and heat signatures make the hybrid variant well-suited for sensitive missions.
Crewed and uncrewed capabilities: Hybrid-electric technology capable of being deployed autonomously, remotely, or with a pilot. Uncrewed capabilities can be seamlessly integrated into the existing Flight Control System being developed by Honeywell.
Mission resilience: Built off the VX4's industry-leading redundancy and damage tolerance, boosting confidence for mission-critical operations.
'The demand for long-range, high-payload, quiet aircraft is growing rapidly - especially across defense and critical logistics.' said Stuart Simpson, CEO of Vertical Aerospace. 'Our hybrid-electric VTOL strategy builds on our existing electric platform, world-class battery technology and large, versatile airframe, allowing us to offer uniquely scalable solutions that unlock a new frontier in air mobility and revenue stream for Vertical.'
Best-in-class hybrid-electric potential enabled by proprietary battery technology and airframe
Vertical's proprietary battery platform, developed at its purpose-built Vertical Energy Centre, is a critical component of its hybrid-electric capability.
Vertical's battery will help power the superior hybrid range and payload capabilities, enabling best-in-class performance for mission-critical use cases. Vertical's hybrid team has developed advanced control systems supporting safe operation and redundancy, meeting strict European Union Aviation Safety Agency (EASA) and UK Civil Aviation Authority (CAA) safety standards for eVTOL flight. Bench testing has already validated its hybrid-electric architecture, including the successful integration of control algorithms between the power unit and battery.
The VX4's large and flexible airframe enables the integration of hybrid-electric propulsion technology and superior payload capacity without requiring major redesign. This design freedom supports both operational scalability and mission versatility - advantages that smaller platforms may struggle to accommodate.
Uniquely positioned to meet the growing defence needs across Europe
As the only remaining credible European eVTOL company, Vertical's hybrid-electric capabilities position it as a key player amid growing defence budgets and increasing focus on sovereign industrial capacity. As European governments increasingly look to develop new technologies and platforms to strengthen their defence capabilities, Vertical is actively engaged in discussions with government agencies, as well as other prospective customers, around defence applications and other potential use cases for its hybrid-electric aircraft.
Building on all electric VX4 and Flightpath 2030
The hybrid-electric variant will be in addition to Vertical's all-electric VX4, which remains on target for its Flightpath 2030 goal of Type Certification in the UK and Europe in 2028, followed by validation by global regulatory authorities.
About Vertical Aerospace
Vertical Aerospace is a global aerospace and technology company pioneering electric aviation. Vertical is creating a safer, cleaner and quieter way to travel. Vertical's VX4 is a piloted, four passenger, Electric Vertical Take-Off and Landing (eVTOL) aircraft, with zero operating emissions. Vertical combines partnering with leading aerospace companies, including GKN, Honeywell and Leonardo, with developing its own proprietary battery and propeller technology to develop the world's most advanced and safest eVTOL.
Vertical has c.1,500 pre-orders of the VX4, with customers across four continents, including American Airlines, Japan Airlines, GOL and Bristow. Certain customer obligations are expected to be fulfilled via third-party agreements. Headquartered in Bristol, the epicentre of the UK's aerospace industry, Vertical's experienced leadership team comes from top tier automotive and aerospace companies such as Rolls-Royce, Airbus, GM and Leonardo. Together they have previously certified and supported over 30 different civil and military aircraft and propulsion systems.
Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, our ability to integrate hybrid technology into the VX4 on any particular timelines or at all, the ability of the hybrid-electric VX4 variant VX4 to be applied in defense, cargo, logistics and emergency services sectors, our ability to scale the hybrid-electric VX4 upon the VX4, the design and manufacture of the VX4, certification and the commercialization of the both the VX4 and the hybrid-electric VX4 variant and our ability to achieve regulatory certification of our aircraft product on any particular timeline or at all, the features and capabilities of the VX4 and the hybrid-electric VX4 variant, trends in sovereign defense budgets, business strategy and plans and objectives of management for future operations, including the building and testing of our prototype aircrafts on timelines projected, completion of the piloted test programme phases, selection of suppliers, as well as statements that include the words 'expect,' 'intend,' 'plan,' 'believe,' 'project,' 'forecast,' 'estimate,' 'may,' 'should,' 'anticipate,' 'will,' 'aim,' 'potential,' 'continue,' 'is/are likely to' and similar statements of a future or forward-looking nature. These forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation: our limited operating history without manufactured non-prototype aircraft or completed eVTOL aircraft customer order; our potential inability to raise additional funds when we need or want them, or at all, to fund our operations; our limited cash and cash equivalents and recurring losses from our operations raise significant doubt (or raise substantial doubt as contemplated by PCAOB standards) regarding our ability to continue as a going concern; our potential inability to produce or launch aircraft in the volumes or timelines projected; the potential inability to obtain the necessary certifications for production and operation within any projected timeline, or at all; the inability for our aircraft to perform at the level we expect and may have potential defects; our history of losses and the expectation to incur significant expenses and continuing losses for the foreseeable future; the market for eVTOL aircraft being in a relatively early stage; any accidents or incidents involving eVTOL aircraft could harm our business; our dependence on partners and suppliers for the components in our aircraft and for operational needs; the potential that certain strategic partnerships may not materialize into long-term partnership arrangements; all of the pre-orders received are conditional and may be terminated at any time and any predelivery payments may be fully refundable upon certain specified dates; any circumstances; any potential failure to effectively manage our growth; our inability to recruit and retain senior management and other highly skilled personnel; we have previously identified material weaknesses in our internal controls over financial reporting which if we fail to properly remediate, could adversely affect our results of operations, investor confidence in us and the market price of our ordinary shares; as a foreign private issuer we follow certain home country corporate governance rules, are not subject to U.S. proxy rules and are subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company; and the other important factors discussed under the caption 'Risk Factors' in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ('SEC') on March 11, 2025, as such factors may be updated from time to time in the Company's other filings with the SEC. Any forward-looking statements contained in this release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this release whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
1 Morgan Stanley 'eVTOL/Urban Air Mobility TAM Update: A Slow Take-Off, But Sky's the Limit' (May 6, 2021).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Prosperity Bancshares (NYSE:PB) shareholders have earned a 7.5% CAGR over the last five years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. But Prosperity Bancshares, Inc. (NYSE:PB) has fallen short of that second goal, with a share price rise of 22% over five years, which is below the market return. Looking at the last year alone, the stock is up 15%. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. Over half a decade, Prosperity Bancshares managed to grow its earnings per share at 1.8% a year. This EPS growth is slower than the share price growth of 4% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that Prosperity Bancshares has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Prosperity Bancshares will grow revenue in the future. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Prosperity Bancshares' TSR for the last 5 years was 43%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! It's nice to see that Prosperity Bancshares shareholders have received a total shareholder return of 19% over the last year. And that does include the dividend. That's better than the annualised return of 7% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Prosperity Bancshares better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Prosperity Bancshares , and understanding them should be part of your investment process. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
34 minutes ago
- Yahoo
Will Elliott's Push Mean Break-up Boost for Phillips 66?
Following a recent proxy battle and boardroom fight, activist investor Elliott Management is well on its way to oversee an unlocking of substantial value trapped by Phillips 66's (NYSE:PSX) conglomerate structure. This article will look at what has happened between Phillips 66 and Elliott Management and what I expect to happen going forward. Phillips 66, which was spun off from ConocoPhillips (COP) in 2012 is operates in the Oil & Gas Refining & Marketing sector. The term Refining & Marketing can also be known as Downstream in the oil and gasindustry. As at the end of Q1 2025, Phillips 66 had five operating segments: Midstream, Chemicals, Refining, Marketing and Specialities, and Renewable Fuels. Warning! GuruFocus has detected 8 Warning Sign with PSX. By contrast, larger peer Marathon Petroleum (NYSE:MPC) has three operating segments: Refining & Marketing, Midstream, and Renewable Diesel. Its midstream operations are primarily conducted through MPLX (MPLX), a master limited partnership listed on the New York Stock Exchange under the ticker MPLX. Marathon Petroleum owns the general partner and a majority limited partner interest in MPLX. Valero Energy (NYSE:VLO), another PSX peer also has just three operating segments: Refining, Renewable Diesel, and Ethanol. If we look at ExxonMobil's (XOM) downstream business, which Exxon calls Product Solutions, it consists also of three segments: Energy Products, Chemical Products, and Specialty Products. Midstream companies tend to run as separate entities, operating in the Oil & Gas Storage & Transportation sub-sector. Examples would include MPLX, or Kinder Morgan (KMI), or Williams (WMB). So, a very simplistic view would suggest Phillips 66 operates in an unwieldy manner. This typically causes a conglomerate discount, which activist investor Elliott is known for attacking. According to Elliott's April 28, 2025 presentation titled Streamline 66: Elliott's Perspectives on Value Creation In September 2023, Elliott approached Phillips 66 with a clear message: its assets were significantly undervalued and underperforming. Initially, the Company acknowledged challenges, particularly in refining, reaffirmed its $14 billion mid-cycle EBITDA target and the Executive Chairman announced his retirement. Elliott released a statement stating the Company leadership deserved investor support so long as they demonstrated meaningful progress against their targets over the following year, but if performance did not improve more change would be needed. To support long-term value creation, Elliott sought to enhance the Board by adding two directors with relevant industry expertise. Yet cooperation quickly stalled. Despite the quality of the candidates proposed, Phillips 66 was slow to act and ultimately rejected several well-qualified individuals. Only after Elliott formally submitted nominations did the Company appoint Bob Pease to the Board in February 2024. In addition, throughout 2024 the Company's operating performance deteriorated and the Company continues to be woefully short of its EBITDA target. Since February 2025, Elliott has been more public about itsposition, with a campaign called Streamline 66. Its goals, according to the Perspectiveson Value Creation presentation, were fourfold: Improve accountability of Phillips 66's management by adding credible directors with a mandate for change Unlock substantial value trapped by Phillips 66's conglomerate structure Refocus the Company on operational excellence by adding deep industry expertise to the Board Instill a culture of ambition where Phillips 66 aims to be the top performing refining company in the world Elliott's core idea is that Midstream should trade at about 9-12x EBITDA, while Refining and Chemicals should trade at 6-7x EBITDA. Elliott notes that PSX trades like a refiner, therefore undervaluing the Midstreambusiness, due to a large conglomerate discount. Elliott is also saying that PSX's refining profitability dramatically lags peers. According to the Perspectives on Value Creation presentation, Elliott also used a third-party refining industry analytics firm, Baker & O'Brien and its PRISM Model to help understand the intrinsic profitability of Phillips 66's refinery assets relative to its actual results and peers. Before I came a full-time investor, I used to work in oil trading, and Baker & O'Brien PRISM Model was a sophisticated tool to understand how refineries could optimize their performance. So, it is quite impressive that Elliott has utilized this in their analysis of PSX's refining business. The Perspectives on Value Creation presentation slides 80 through 87 analyse PSX's regional competitiveness and concludes that PSX's refining assets are comparable to peers Marathon and Valero its underperformance is primarily driven by pooroperational execution, rather than the quality of the assets. But why should we care about what Elliott thinks? Well, Elliott has recent form in Refining & Marketing where it started an engagement with Marathon Petroleum in 2019 which resulted in a new executive leadership, the saleof Speedway to 7-Eleven for about $17 billion, and improved operating performance with proceeds used to repurchase its own shares. The stock has risen dramatically in the last five years. Elliott also pushed other large companies to realize value from their conglomerate discounts. Two recent examples I have followed include GSK plc (GSK) where in 2021 it called for a full separation of its Biopharmaand Consumer Health businesses, resulting ultimately in Haleon plc (HLN) being spun out into an independent Consumer Health business. In 2017 Elliott began pushing for BHP plc (BHP) to unify its dual-listed structure and for the metals and mining company to exit its petroleum business. By 2021, BHP moved its primary listing to Sydney, removing its complex dual-listed structure, and became a more streamlined and focused mining company, returning substantial funds to shareholders. Following more than a year of apparently contentious engagement, Elliott started a proxy fight to replace four board members at the 2025 shareholder meeting. While the campaign was backed by the three main proxyadvisory firms ISS, Glass Lewis and Egan-Jones, Phillips 66's largest passive investors (BlackRock, Vanguard, State Street), who sided with the company. This is likely because many of the shares held by BlackRock, Vanguard, State Street are in index tracking vehicles PSX is a S&P 500 constituent and they don't tend to ever vote against managements. In my opinion each of the four board members Elliott was proposing were highly qualified to sit on the board of a Refining & Marketing company. On May 21, 2025, the proxy contest concluded with a split result. Elliott won two board seats for Sigmund Cornelius and Michael Heim and PSX won the other two seats, for Bob Pease and Nigel Hearne. The case of Bob Pease is interesting. He was originally blessed by Elliott joining PSX's board in February 2024, but a year later, Elliott wanted him replaced. In a letter to shareholders Mr Pease said I do not know why Elliott now wants me off the Board. But Elliott wrote in its Perspectives on Value Creation presentation that Mr. Pease has failed to acknowledge Phillips' clear performance issues and has adopted the Company's empty,self-congratulatory rhetoric. GuruFocus News also noted that a proposal to "declassify the Board of Directors over a three-year period was not approved" by the shareholders. Also, a non-binding shareholder proposal requesting the Board toadopt a policy requiring directors to submit a resignation letter effective at the next annual meeting was not approved. Elliott wanted PSX to have board membership voted on each year, as is best practise for corporate governance but this was rejected in the vote. Elliott in a press release following the vote said it will continue to actively engage with the Company while holding management and the Board accountable for delivering on their commitment to improve shareholdervalue. As we have seen before, Elliott is a patient activist investor. The two board members they have managed to get on the board Sigmund Cornelius and Michael Heim are industry veterans. Cornelius is a former Chief Financial Officer of ConocoPhillips, and was previously on the board of Chevron Phillips Chemical Company, now a PSX joint venture with Chevron (CVX) which Elliott wants PSX to divest. Cornelius in an Elliott presentation said of his priorities upon joining the board: It's a different structure than Marathon or Valero and they have been the better performers. I will insist that we take a harder look at this structure. Heim is one of the founders and former President and Chief Operating Officer of Targa Resources (TRGP) which is an important midstream company and one of the New York Stock Exchange's largest stocks in the Oil & Gas Storage & Transportation subsector. Heim served in numerous executive leadership roles over the course of over 16 years at Targa and said in an Elliott presentation Midstream businesses can be growth engines, but they need the right structure to compete. Phillips' midstream business is constrained in so many ways in the current structure. I think people will be amazed at what is possible with these assets. So, it's clear to me that Elliott will still push hard for a separation of PSX's midstream segment. With a consensus Midstream segment EBITDA of about $4.1 billion, and at a 9.7x multiple Elliott sees Midstream achieving gross proceeds of about $39.5 billion. The TEV/EBITDA multiple of 9.7x is based on an average of Midstream peers Enterprise Products Partners (EPD), MPLX, ONEOK, Inc (OKE), and Targa Resources. It also sees a sale of CPChem grossing $13 billion, which is derived as a mid-cycle EBITDA of $1.9 billion at a TEV/EBITDA multiple of 6.4x using Dow Inc (DOW) and LyondellBasell Industries (LYB) as peers, plus $750 million in saved outlay on capex for a CPChem expansion project. On Elliott's calculations (slide 133 of Perspectives on Value Creation) PSX could be worth between $151 and $169 per share in the near term, based on a sum of the parts valuation: Source: Elliott's Perspectives on Value Creation, April 28, 2025 / The City LetterNote that PSX announced in May it is selling JET business in Germany and Austria $2.8 billion enterprise value, which is close enough to Elliott's $3.0 billion enterprise value assumption. This sale is an indication that PSX is already taking on board some of Elliott's demands. Assuming PSX spins Midstream at $39-40 billion, then the key for the $169 price target is if PSX can achieve refining EBITDA per barrel at parity with Valero, based on 2026 expected throughput. The Baker & O'Brien refining assets analysis suggests that "the kit", the refinery systems themselves, can do this. It's now just a question of management ambition. It may have been better had Brian Coffman been nominated to the board, given his refining expertise, but I expect Elliott will monitor this and revisit it in the future if improvements don't start coming through. Phillips 66 has the GF Score of 72, which implies that the company is Likely to have average performance. Without Elliott shaking things up, that's probably what could be expected going forward. Meanwhile Marathon Petroleum has a GF Score of 80 and Valero Energy has a GF Value score of 78. PSX underperforms mainly because it scores a Growth Rank of 2/10. The Growth Rank is scored through revenue growth and EBITDA growth. PSX's lower growth rank aligns with Elliott's point that PSX has been underperforming and could do better with renewed management drive and better refining performance. Like Marathon Petroleum, PSX has a Moat score of 7, which means Entry-level wide moat, clearly possessing durable advantages This also confirms Elliott's thesis that PSX has a lot of potential if management can beshaken up. As minority investors, we can almost freeride on the back of Elliott. The only things to note are that Elliott could walk away at any time, although I think that is unlikely and that Elliott may have some macro hedges in place founder Paul Singer told the In Good Company podcast earlier this year that that is usually the case in their investments. This means Elliott may be less exposed to the macro risks that are inherent in PSX: refining and chemical margins and midstream volumes. So, any standalone investment, without hedges, would incur these risks. In my opinion, as part of a diversified portfolio, a minority investor can bear these risks and look torealize the significant upside that Elliott is looking to squeeze out, which at the time of writing is about 30%. Elliott has a strong track record of patiently encouraging and sometimes forcing companies to rid their conglomerate discount through business spin-offs and changes at the board and executive management level. The May 2025 annual shareholder vote was a partial victory for Elliott and I expect the new board members Sigmund Cornelius and Michael Heim to put forth the case to spin out the PSX Midstream business, which may take 12-18 months to fully execute. Investors can afford to wait for this value to be realized over time. PSX has an Altman Z-score of 3.43 which is strong and means there is no immediate financial danger. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
38 minutes ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
